Login to Your Account



Repligen Drops on Phase IIb Failure in Bipolar Depression

By Catherine Shaffer


Tuesday, March 8, 2011
A Phase IIb study of a compound for bipolar depression by Repligen Corp., of Waltham, Mass., failed to reach statistical significance compared to placebo, sending the company's stock into a tailspin Monday.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription